Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
3.665
+0.465 (14.53%)
At close: Aug 21, 2026, 4:00 PM EDT
3.660
-0.005 (-0.14%)
After-hours: Aug 21, 2026, 7:14 PM EDT

Bolt Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4.77.77.697.885.731.26
Revenue Growth
12.79%0.07%-2.36%37.48%354.68%445.46%
Cost of Revenue
21.528.5357.4761.5473.1275.66
Gross Profit
-16.8-20.84-49.78-53.67-67.39-74.4
Selling, General & Admin
11.6713.818.4622.5322.9318.39
Operating Expenses
11.6713.818.4622.5322.9318.39
Operating Income
-28.48-34.63-68.24-76.2-90.32-92.79
Interest & Investment Income
1.32.55.2672.220.28
Other Non Operating Income (Expenses)
0.730.24----6.08
EBT Excluding Unusual Items
-26.45-31.9-62.98-69.2-88.1-98.59
Merger & Restructuring Charges
-1.48-1.48-3.34---
Asset Writedown
-0.81--1.47---
Other Unusual Items
--4.68---
Pretax Income
-28.74-33.38-63.12-69.2-88.1-98.59
Net Income
-28.74-33.38-63.12-69.2-88.1-98.59
Net Income to Common
-28.74-33.38-63.12-69.2-88.1-98.59
Net Income Growth
------
Shares Outstanding (Basic)
222222
Shares Outstanding (Diluted)
222222
Shares Change
-8.42%-2.06%0.98%1.21%12.54%1479.05%
EPS (Basic)
-16.38-17.85-33.06-36.60-47.16-59.40
EPS (Diluted)
-16.38-17.85-33.06-36.60-47.16-59.40
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-31.54-39.92-61.33-69.73-78.46-59.4
Free Cash Flow Per Share
-17.98-21.35-32.12-36.88-42.00-35.79
Gross Margin
--270.80%----
Operating Margin
-605.85%-450.07%-887.33%-967.45%-1576.56%-7364.13%
Profit Margin
-611.47%-433.74%-820.78%-878.58%-1537.75%-7824.68%
Free Cash Flow Margin
-670.98%-518.80%-797.53%-885.36%-1369.47%-4714.60%
EBITDA
-27.56-33.34-66.46-74.34-88.66-91.6
D&A For EBITDA
0.921.291.781.851.671.19
EBIT
-28.48-34.63-68.24-76.2-90.32-92.79
SEC Filings: 10-K · 10-Q